New Liver Failure Warning For Antibiotic

Jamie Sheller
Attorney
(866) 735-1102 Ext 475
Posted by Jamie ShellerJune 30, 2006 1:55 PM

The FDA has approved new safety warnings for the label of the antibiotic Ketek (telithromycin). There have been several reports of serious liver injury and liver failure associated with Ketek. The FDA advises Ketek users and their doctors to watch for signs of liver problems, which include dark-colored urine, fatigue, yellow skin and malaise. However, "the agency has concluded that the drugs' benefit to patients for the approved indications outweighs its risk, including the rare risk of liver failure, and supports its continued availability." Ketek is used to treat chronic bronchitis, community acquired pneumonia and acute bacterial sinusitis.

0 Comments

Have an opinion about this post? Please consider leaving a comment or subscribing to the feed to have future articles delivered to your feed reader.

Comments for this article are closed.

Subscribe to InjuryBoard Philadelphia

InjuryBoard Philadelphia RSS Feeds

Keep up with the latest updates using your favorite RSS reader

Injury Board Philadelphia is brought to you by Sheller, P.C.

Legal Assistance Center

More Info
Sheller, P.C. (866) 735-1102 Ext 475 www.sheller.com
google
Personal Injury Lawyers Serving: Statewide Pennsylvania, Philadelphia, Norristown, Cheltenham, Chester, Drexel Hill, Folsom, Havertown, King of Prussia, Levittown, Radnor, Springfield, Swarthmore, West Chester, Willow Grove
1528 Walnut Street3rd Floor, Philadelphia, Pennsylvania 19102 [ Show Map ]
Better Business Bureau Accredited Business Confidential

Your question will be referred to an attorney near you. If your question is of a legal nature, then by submitting this form you agree you are not forming a formal attorney / client relationship. Read our full privacy policy.

Looking for an InjuryBoard attorney closer to home? Click here.

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address